Supply Chain
Long wait times, crowded waiting rooms, and frustrated staff are often symptoms of inefficient workflows driven by physical space constraints.…
Here are the seven latest drugs or medical devices approved by the FDA this week.
The FDA approved the first blood test in the U.S. to help physicians detect mild traumatic brain injury, or concussions, in adults.
The FDA sent a warning letter to Bayer Nov. 14 over various quality control issues at the drugmaker's headquarters in Leverkusen, Germany.
Janssen Pharmaceutical Co., a subsidiary of Johnson & Johnson, earned FDA approval Wednesday for its prostate cancer drug, Erleada.
A team of biochemistry, chemistry and mechanical engineering researchers at the University of Colorado Boulder developed a self-healing "electronic skin," or "e-skin," the university announced Feb. 9.
FDA Commissioner Scott Gottlieb, MD, on Feb. 13 laid out plans for a Center of Excellence on Digital Health as part of the agency's request for 2019 funding.
While Deerfield, Ill.-based Walgreens Boots Alliance is reportedly in discussions to acquire AmerisourceBergen, analysts speculate the move may fail to keep Walgreens competitive in an ever-changing healthcare market, Reuters reports.
The FDA cleared Viz.AI, a San Francisco-based health IT company, to market its clinical decision support software for stroke care Feb. 13.
Bristol-Myers Squibb will pay Nektar Therapeutics $1 billion to develop a cancer immunotherapy treatment — one of the largest deals ever inked for a single drug's development, reports Reuters.
The FDA approved Teligent's betamethasone dipropionate lotion Wednesday.